Experts in Visual Communication of information & statistical data. Specializing in FDA Advisory Committee presentation support.
Connecticut
Joined January 2014
- Tweets410
- Following46
- Followers16
- Likes224
VĭZEN /ˈvĭ-zhən/ retweeted
Exciting news! Alzheon joins @Oppenheimer 34th Annual Healthcare Life Sciences Conference, influencing the future of healthcare. Our CFO, Ken Mace, presents on Feb 14th. Follow for updates on advancing Oral ALZ-801. alzheon.com/
#Alzheimers #dementia
VĭZEN /ˈvĭ-zhən/ retweeted
Today, we reported positive safety, biomarker, and clinical results from our Phase 2 trial of oral ALZ-801 in patients with Early #Alzheimers disease who are APOE4 carriers. Full press release: rb.gy/zpnei
VĭZEN /ˈvĭ-zhən/ retweeted
Excited to announce that the Alzheon team is Amsterdam-bound for the highly anticipated #AAIC23! Meet us at booth #700 to learn about the science behind our research. See you there!
@alzassociation
#neurology #Alzheimers
VĭZEN /ˈvĭ-zhən/ retweeted
In Part 2, APOE Genotyping in Clinical Practice: Pros and Cons, @MarwanSabbaghMD discusses the rising popularity of APOE genotype testing despite concerns related to the disclosure of genetic information. Click below to watch.
#alzheimers
mdlinx.com/specials/s/preser…
VĭZEN /ˈvĭ-zhən/ retweeted
Join Alzheon, CSO, John Hey, PhD today at #AANAM for a podium presentation: Effects of ALZ-801, an Oral Amyloid Oligomer Inhibitor, on Biomarkers of Alzheimer’s Disease (AD): 12-Month Results of Phase 2 Biomarker Study in Early AD 2:12 pm, S26.
#alzheimers #AAN2023
@AANmember
VĭZEN /ˈvĭ-zhən/ retweeted
Poster: Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer's Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate). #dementia #Alzheimers
VĭZEN /ˈvĭ-zhən/ retweeted
Interested in learning more about the latest developments with ALZ-801? Catch us Monday, April 24, during poster session 5 for a poster presentation and Tuesday, April 25, 2:12 p.m., S26 for a podium presentation at #AAN2023
#ALZ-801 continued to demonstrate its potential as a disease-modifying therapy for #AD, represented by reductions in plasma phosphorylated-tau 181, slowing of hippocampal atrophy, and stabilization of cognition. @Alzheon @AANmember #AAN2023
View: ow.ly/aqkJ50NPp9C
VĭZEN /ˈvĭ-zhən/ retweeted
The Alzheon team is excited to have #AAN2023 in our backyard this year. We look forward to seeing everyone.
#neurology #Alzheimers @AANmember
VĭZEN /ˈvĭ-zhən/ retweeted
We’re excited to be featured in @ForbesCesko's recent article in the Czech Republic on Alzheon as “A Unicorn on the Horizon!”
#Alzheimers
forbes.cz/jednorozec-na-obzo…
VĭZEN /ˈvĭ-zhən/ retweeted
At #ADPD2023? Don’t miss Alzheon CEO, @MartinTolar, MD, PhD, today when he presents at the podium: Significant Biomarker Effects of Oral Anti-Amyloid Agent ALZ-801 In Phase 2 Study In APOE4 Carriers With Early Alzheimer’s Disease. 6:50PM CET, Hall C.
#Alzheimer #ENDALZ
VĭZEN /ˈvĭ-zhən/ retweeted
The Alzheon team will be on the road to Gothenburg, Sweden for #ADPD2023 shortly. We look forward to seeing everyone.
#neurology #ENDALZ
alzheon.com/alzheon-to-prese…
VĭZEN /ˈvĭ-zhən/ retweeted
Featured on the @NYSE “The Cure(ious)” special, hear what drives Alzheon CEO, @MartinTolar, MD, PhD.
lnkd.in/eTFSghpZ
VĭZEN /ˈvĭ-zhən/ retweeted
Future Plans for ALZ-801 in Homo- and Heterozygous Populations: In a discussion with @neurology_live, Chief Medical Officer, Susan Abushakra, MD, provides insight on next steps for ALZ-801.
neurologylive.com/view/futur…
#ENDAlz #dementia
VĭZEN /ˈvĭ-zhən/ retweeted
At Alzheon, our team is working hard to potentially offer the first precision medicine approach to treat APOE4 homozygotes in the fight against #Alzheimer’s.
#CTAD22 #ENDAlz
VĭZEN /ˈvĭ-zhən/ retweeted
Join Alzheon CMO, Susan Abushakra, MD, tomorrow @CTADconference, 11:45 a.m. PT, when she presents at the podium: The effects of oral ALZ-801 on plasma biomarkers of Alzheimer’s disease.
#Alzheon #ENDALZ #DementiaAwareness #ctad2022
VĭZEN /ˈvĭ-zhən/ retweeted
If you’re @CTAD22, Dr. @MartinTolar Founder, President & CEO of Alzheon invites you to join the #Alzheon team for a company reception this evening at 5pm PT. Join us in the Vista Room, in Hilton San Francisco Union Square, on the 45th floor in Tower 1.
#ENDALZ
VĭZEN /ˈvĭ-zhən/ retweeted
Alzheon CEO, @MartinTolar and the team are looking forward to #CTAD2022 in San Francisco. If you will be attending, don’t miss our podium presentation on December 2nd at 11:45am PT!
#Alzheon #EndALZ #DementiaAwareness @CTADconference
VĭZEN /ˈvĭ-zhən/ retweeted
2/ The podium presentation will take place in person on Friday, December 2nd at 11:45 a.m. PT or 2:45 p.m. ET during the “Interim or Preliminary Data and Study Design” focus session. Read the full announcement here: alzheon.com/alzheon-to-prese…
#APOLLOE4 #EndAlzheimers #APOE4
VĭZEN /ˈvĭ-zhən/ retweeted
1/ Alzheon is excited to announce that it will be presenting its latest Phase 2 biomarker, brain preservation, and clinical effects with oral ALZ-801 (valiltramiprosate) at @CTADconference in San Francisco!
#CTAD2022 #Alzheon #EndALZ #DementiaAwareness